Medicure (MCUJF) Income from Non-Controlling Interests (2017)
Medicure's (MCUJF) quarterly Income from Non-Controlling Interests came in at $5.7 million in Q4 2017, up 373.86% quarter-over-quarter from $1.2 million in Q3 2017.
Medicure (MCUJF) Income from Non-Controlling Interests (2017) Analysis & Trends
Medicure's Income from Non-Controlling Interests history runs 1 years deep, the most recent figure standing at $5.7 million for Q4 2017.
- On a quarterly basis, Income from Non-Controlling Interests changed N/A year-over-year to $5.7 million in Q4 2017; TTM through Dec 2017 was $8.9 million, a N/A change from a year earlier, with the FY2017 full-year figure at $5.6 million, changed N/A from the prior year.
- Income from Non-Controlling Interests grew to $5.7 million in Q4 2017 per MCUJF's latest filing, from $1.2 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $5.7 million in Q4 2017 and bottomed at $893606.3 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Medicure | 8.77 Mn | 7.64 Mn | 2.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 5.68 Mn |
| Sep 30, 2017 | 1.20 Mn |
| Jun 30, 2017 | 1.15 Mn |
| Mar 31, 2017 | 893,606.31 |